학술논문

EBSCO Discovery Service
발행년
-
(예 : 2010-2015)
'학술논문' 에서 검색결과 88건 | 목록 1~10
Academic Journal
Mostböck S; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Wu HH; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.; Fenn T; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.; Riegler B; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Strahlhofer S; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Huang Y; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.; Hansen G; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.; Kroe-Barrett R; Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.; Tirapu I; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Vogt AB; Cancer Immunology and Immune Modulation, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Academic Journal
Zettl M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Wurm M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Schaaf O; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Mostböck S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Tirapu I; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Apfler I; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Lorenz IC; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.; Frego L; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.; Kenny C; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.; Thibodeau M; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.; Oquendo Cifuentes E; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.; Reschke M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Moll J; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Kraut N; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Vogt A; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Sedgwick JD; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.; Waizenegger IC; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE
Academic Journal
Wurm M; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Pharmacology and Disease Positioning, Vienna, Austria.; Schaaf O; Boehringer Ingelheim RCV, GmbH & Co KG, Drug Discovery Sciences, Vienna, Austria.; Reutner K; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria.; Ganesan R; Boehringer Ingelheim Pharmaceuticals, Inc., Biotherapeutics Discovery, Ridgefield, Conneticut.; Mostböck S; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria.; Pelster C; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria.; Böttcher J; Boehringer Ingelheim RCV, GmbH & Co KG, Drug Discovery Sciences, Vienna, Austria.; de Andrade Pereira B; Boehringer Ingelheim Pharma GmbH, Cancer Immunology and Immune Modulation, Biberach, Germany.; Taubert C; Allcyte GmbH, Vienna, Austria.; Alt I; Allcyte GmbH, Vienna, Austria.; Serna G; Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology, CIBERONC, Universitat Autonoma de Barcelona, Barcelona, Spain.; Auguste A; Boehringer Ingelheim Pharma GmbH & Co KG, Translational Medicine and Clinical Pharmacology, Biberach, Germany.; Stadermann KB; Boehringer Ingelheim Pharma GmbH & Co KG, Translational Medicine and Clinical Pharmacology, Biberach, Germany.; Delic D; Boehringer Ingelheim Pharma GmbH & Co KG, Translational Medicine and Clinical Pharmacology, Biberach, Germany.; Han F; Boehringer Ingelheim Pharmaceuticals, Inc., Biotherapeutics Discovery, Ridgefield, Conneticut.; Capdevila J; Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology, CIBERONC, Universitat Autonoma de Barcelona, Barcelona, Spain.; Nuciforo PG; Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology, CIBERONC, Universitat Autonoma de Barcelona, Barcelona, Spain.; Kroe-Barrett R; Boehringer Ingelheim Pharmaceuticals, Inc., Biotherapeutics Discovery, Ridgefield, Conneticut.; Adam PJ; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria.; Vogt AB; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria.; Hofmann I; Boehringer Ingelheim RCV, GmbH & Co KG, Cancer Immunology and Immune Modulation, Vienna, Austria. irmgard.hofmann@boehringer-ingelheim.com.
Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Academic Journal
Zelba H; Department of Immunology, University of Tübingen, Tübingen, Germany. henning_zelba@gmx.de cecile.gouttefangeas@uni-tuebingen.de.; Bedke J; Department of Urology, University Hospital Tübingen, Tübingen, Germany.; Hennenlotter J; Department of Urology, University Hospital Tübingen, Tübingen, Germany.; Mostböck S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Zettl M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Zichner T; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.; Chandran A; Department of Immunology, University of Tübingen, Tübingen, Germany.; Stenzl A; Department of Urology, University Hospital Tübingen, Tübingen, Germany.; Rammensee HG; Department of Immunology, University of Tübingen, Tübingen, Germany.; Gouttefangeas C; Department of Immunology, University of Tübingen, Tübingen, Germany. henning_zelba@gmx.de cecile.gouttefangeas@uni-tuebingen.de.
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE
Academic Journal
Schmid T; Institute of Immunology, University of Regensburg, Regensburg, Germany.; Falter L; Institute of Immunology, University of Regensburg, Regensburg, Germany.; Weber S; Institute of Immunology, University of Regensburg, Regensburg, Germany.; Müller N; Institute of Immunology, University of Regensburg, Regensburg, Germany.; Molitor K; Institute of Immunology, University of Regensburg, Regensburg, Germany.; Zeller D; Institute of Immunology, University of Regensburg, Regensburg, Germany.; Weber-Steffens D; Institute of Immunology, University of Regensburg, Regensburg, Germany.; Institute of Immunology, Regensburg Center for Interventional Immunology (RCI), University Medical Center, Regensburg, Germany.; Hehlgans T; Institute of Immunology, University of Regensburg, Regensburg, Germany.; Institute of Immunology, Regensburg Center for Interventional Immunology (RCI), University Medical Center, Regensburg, Germany.; Wajant H; Division of Molecular Internal Medicine, Department of Medicine II, University Hospital Würzburg, Würzburg, Germany.; Mostböck S; Institute of Immunology, University of Regensburg, Regensburg, Germany.; Männel DN; Institute of Immunology, University of Regensburg, Regensburg, Germany.
Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Print ISSN: 1664-3224 (Print) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: PubMed not MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Mostböck, S.
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어